DexCom (DXCM)
(Delayed Data from NSDQ)
$129.65 USD
+1.28 (1.00%)
Updated May 6, 2024 04:00 PM ET
After-Market: $129.67 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
DexCom, Inc. [DXCM]
Reports for Purchase
Showing records 281 - 300 ( 411 total )
Company: DexCom, Inc.
Industry: Medical - Instruments
CGM Project: Historical survey of 1,271 CGM users (2007 - present)
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Instruments
2Q Preview: Expecting Trends to Improve (Slightly)
Provider: WEDBUSH SECURITIES INC.
Company: DexCom, Inc.
Industry: Medical - Instruments
Company: DexCom, Inc.
Industry: Medical - Instruments
Perspectives on the Largest Acquisition in MedTech: A Covidien Primer
Provider: WEDBUSH SECURITIES INC.
Company: DexCom, Inc.
Industry: Medical - Instruments
Perspectives on the Largest Acquisition in MedTech: A Covidien Primer
Provider: WEDBUSH SECURITIES INC.
Company: DexCom, Inc.
Industry: Medical - Instruments
Company: DexCom, Inc.
Industry: Medical - Instruments
Company: DexCom, Inc.
Industry: Medical - Instruments
Company: DexCom, Inc.
Industry: Medical - Instruments
Another Solid Top-Line Performance, But Stock-Based Compensation Weighs on Opex
Provider: WEDBUSH SECURITIES INC.
Company: DexCom, Inc.
Industry: Medical - Instruments
Company: DexCom, Inc.
Industry: Medical - Instruments
1Q Preview: Expecting a Seasonally Soft Quarter but Fundamentals Remain Intact
Provider: WEDBUSH SECURITIES INC.
Company: DexCom, Inc.
Industry: Medical - Instruments
Company: DexCom, Inc.
Industry: Medical - Instruments
Morning Call
Provider: The Benchmark Company
Company: DexCom, Inc.
Industry: Medical - Instruments
Q4 sales inline with preannouncement, EPS ahead, advise profit taking
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Instruments
Growth and Opportunity Continues on Pace; Price Target to $50
Provider: The Benchmark Company
Analyst: WALD J
Company: DexCom, Inc.
Industry: Medical - Instruments
4Q13 Review: Raising Estimates and PT to $48; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: DexCom, Inc.
Industry: Medical - Instruments
Company: DexCom, Inc.
Industry: Medical - Instruments
Morning Call
Provider: The Benchmark Company
Company: DexCom, Inc.
Industry: Medical - Instruments
Receives G4 PLATINUM CGM FDA Approval for Children Ages 2 to 17 -- And an Opportunity to Go Where None have Gone Before (ages 2 to 6)
Provider: The Benchmark Company
Analyst: WALD J
Company: DexCom, Inc.
Industry: Medical - Instruments
Pre-Announcement Points to a Solid Quarter and a Good 2014 Thanks to the Platinum G4 Sensor; Price Target to $44
Provider: The Benchmark Company
Analyst: WALD J